share_log

Invivyd | 10-K: FY2023 Annual Report

Invivyd | 10-K: FY2023 Annual Report

Invivyd | 10-K:2023財年年報
美股SEC公告 ·  03/28 06:19

Moomoo AI 已提取核心訊息

Invivyd, Inc., a commercial-stage biopharmaceutical company, has reported its financial and operational results for the year ended December 31, 2023. The company has not generated any revenue from product sales or other sources and reported a net loss of $198.6 million for the year, with an accumulated deficit of $732.1 million. Despite this, Invivyd successfully completed its initial public offering (IPO), raising net proceeds of approximately $327.5 million. The company's common stock is listed on the Nasdaq Global Market under the symbol 'IVVD'. Invivyd has not declared or paid any cash dividends and does not anticipate doing so in the foreseeable future, as it plans to reinvest all available funds and future earnings into business development and expansion. Invivyd's business development has...Show More
Invivyd, Inc., a commercial-stage biopharmaceutical company, has reported its financial and operational results for the year ended December 31, 2023. The company has not generated any revenue from product sales or other sources and reported a net loss of $198.6 million for the year, with an accumulated deficit of $732.1 million. Despite this, Invivyd successfully completed its initial public offering (IPO), raising net proceeds of approximately $327.5 million. The company's common stock is listed on the Nasdaq Global Market under the symbol 'IVVD'. Invivyd has not declared or paid any cash dividends and does not anticipate doing so in the foreseeable future, as it plans to reinvest all available funds and future earnings into business development and expansion. Invivyd's business development has been marked by the emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for PEMGARDA™, a monoclonal antibody for COVID-19 prevention in certain immunocompromised individuals. The company also nominated VYD2311, another monoclonal antibody, for clinical development. Invivyd's future plans include leveraging its INVYMAB platform to periodically introduce new monoclonal antibody candidates to keep pace with viral evolution, particularly for SARS-CoV-2. The company's strategy involves building its own commercial organization and outsourcing to contract sales and marketing organizations. Invivyd's financial outlook indicates that its existing cash and cash equivalents will fund operations into the fourth quarter of 2024, but there is substantial doubt about the company's ability to continue as a going concern beyond that without additional funding.
生物醫藥公司Invivyd,已經公佈了截至2023年12月31日的財務和業務成果。公司沒有通過產品銷售或其他渠道產生任何收入,在該年報告了19860萬美元的淨虧損,累計赤字爲73210萬美元。儘管如此,Invivyd仍然成功地完成了首次公開招股(IPO),募集了淨收益約爲32750萬美元。公司普通股在納斯達克全球市場上掛牌交易,交易標的爲“IVVD”。Invivyd尚未宣佈或支付任何現金股利,並且不預計在可預見的未來這樣做,因爲其計劃將所有可用資金和未來收益重新投資於業務發展和擴張中。Invivyd的業務發展得到了美國食品和藥品管理局(FDA)的緊急使用授權(EUA),用於針對某些免疫系統受損...展開全部
生物醫藥公司Invivyd,已經公佈了截至2023年12月31日的財務和業務成果。公司沒有通過產品銷售或其他渠道產生任何收入,在該年報告了19860萬美元的淨虧損,累計赤字爲73210萬美元。儘管如此,Invivyd仍然成功地完成了首次公開招股(IPO),募集了淨收益約爲32750萬美元。公司普通股在納斯達克全球市場上掛牌交易,交易標的爲“IVVD”。Invivyd尚未宣佈或支付任何現金股利,並且不預計在可預見的未來這樣做,因爲其計劃將所有可用資金和未來收益重新投資於業務發展和擴張中。Invivyd的業務發展得到了美國食品和藥品管理局(FDA)的緊急使用授權(EUA),用於針對某些免疫系統受損個體預防COVID-19的單克隆抗體PEMGARDA™。該公司還提名另一種單克隆抗體VYD2311開展臨床開發。Invivyd的未來計劃包括利用其INVYMAb平台定期引入新的單克隆抗體候選者,以跟上病毒進化的步伐,特別是針對SARS-CoV-2。該公司的策略包括建立自己的商業組織並外包給承包銷售和營銷組織。Invivyd的財務前景表明,其現有的現金及現金等價物將資助到2024年第四季度,但存在重大質疑該公司是否可以在沒有額外資金的情況下繼續作爲一個運營下去的企業。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息